Piper Jaffray analyst Tyler Van Buren kept his Overweight rating and $200 price target on BeiGene (BGNE) after its Q3 results, saying the company had produced another “strong quarter of commercial execution as the Celgene (CELG) products were up significantly”. The analyst notes that these products’ contribution may be small to overall valuation, but sees their positive performance as a sign of BeiGene’s ability to commercialize future, larger product opportunities in China. Van Buren adds that the NDA filing for zanubrutinib has a “negligible effect” on his valuation.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.